About Our Team
Helping to improve patient care and outcomes
with products that provide early and specific
insights into clinical conditions.
BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is a significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.
Leadership Team
Peter Mørch Eriksen currently serves as the CEO of BioPorto effective January 9, 2024. He was a member of BioPorto’s Board of Directors from 2021 to 2024 and served as CEO of BioPorto from 2013 to 2021. With over 25 years of experience in the MedTech and life science industries, including roles as CEO of Sense A/S and VP of Medtronic, Peter brings extensive expertise in driving growth, restructuring, and securing funding for technology-intensive and complex companies. He is a seasoned leader with a proven track record in the medical device industry, possessing broad experience in the development and commercialization of medical devices for both small and large MedTech companies. Peter’s background in accounting, complemented by his management experience, further enhances his leadership capabilities.
Other directorships: FluoGuide A/S (Chair), Monsenso A/S (Chair), AptaShape ApS (Board Member), PME Holding ApS.
Niels Høy Nielsen was appointed Executive Vice President & Chief Financial Officer on August 1, 2024. He is a highly skilled leader with over 20 years of leadership experience in finance, operations, mergers and acquisitions, and capital markets. He recently joined BioPorto from ChemoMetec A/S, a Danish Nasdaq-listed Medtech company, where he served as CFO since 2022. Before that, Niels was the VP of Finance at Convatec, Infusion Care, a global provider of medical products focused on the management of chronic conditions. During his decade-long tenure at LEO Pharma A/S, he led departments in finance, sales, and manufacturing. Prior to his tenure with LEO Pharma, he worked 7 years within investment banking at Jyske Bank and Svenska Handelsbanken. Niels holds a Master of Science in Finance and Accounting from the Aarhus School of Business and has supplemented his education with leadership training at IMD.
Gry Husby Larsen was appointed Executive Vice President and Chief Legal Officer in April 2024. Gry has been with BioPorto since 2011, initially as the General Counsel, where she led the company’s legal and HR activities, including compliance, fundraising, intellectual property rights, contracts, Board support, HR, and ESG. From 2019 – 2024, Gry served as an external General Counsel for BioPorto while also holding part-time General Counsel positions at FluoGuide A/S, Algiecel A/S, and Unibio A/S, as well as conducting consultancy work through HUSBY ApS. Before joining BioPorto, Gry was an Attorney-at-law at Knop & Co. Law Firm. Her extensive legal and commercial experience in the biotech industry is a significant asset in the growth and development of BioPorto. Gry holds a Master of Law degree from the University of Copenhagen.
Other directorships: BioPorto Diagnostics A/S (Chair), HUSBY ApS (CEO)
Jennifer Zonderman first joined the US team in May 2019 and is now Senior Vice President Global Marketing & Commercialization. Jennifer excels at leading sales organizations through change such as growth, new markets, product launches and team integrations. Focusing on process and system improvements and developing methods and teams to consistently achieve revenue goals is the key to her success. Jennifer’s sales career has spanned both medical and high tech. She has a Master’s Certificate from Wayne State and a Bachelor of Science from Alma College.
Ursula Klause first joined BioPorto as Vice President of Research and Development in December 2020. She now leads the global clinical and technical development team – a group of highly qualified and motivated professionals passionate about providing superior products to improve patients’ lives. She has a strong scientific background with more than 15 years in assay development and validation, system integration, biomarker discovery, and new technology assessments. Prior to BioPorto, she served as a Senior Scientific Affairs Manager at Roche Diagnostics, where she managed and led industry-supported and industry-sponsored studies and served as point-of-contact for all customer off-label questions regarding assay quality, standardization, and clinical utility. Ursula has a Master’s degree in Nutritional Sciences from the University of Bonn (Germany), and a PhD in Molecular Biology from the University of Cologne (Germany).
Asger Dahlgaard first joined BioPorto as Vice President of Quality Assurance and Regulatory Affairs in October 2021. With more than 20 years in the medical industry, Asger is now focused on ensuring BioPorto’s quality management system is flawless. Asger provides a proven track record in the management of global quality organizations, strategic thinking, and execution. While at Agilent Technologies, Asger managed a team of 45 to provide ongoing quality support including management reviews, and audits (FDA, notifying bodies, internal and vendor). His experience also includes managing and supporting major IT implementations and a new IVD-R system for Complaints, Vigilance, NCR, and Post Market Surveillance. Asger holds a Bachelor of Science in Engineering from the DTU-Technical University of Denmark.
Dr. Prasad Devarajan
Senior Medical Director
With over 40 years of medical experience, Dr. Prasad Devarajan, MD, FAAP, FASN, joined the BioPorto team as Senior Medical Director in July 2022. He is a world-renowned pediatric nephrologist at Cincinnati Children’s Hospital Medical Center in Ohio, where he is the Director of the Nephrology and Hypertension Division, Medical Director of the Stone Center, and Professor at the UC Department of Pediatrics. In addition, Dr. Devarajan is on the editorial and review boards of more than 20 journals and multiple US National Institutes of Health (NIH) study sections. He has authored more than 320 peer-reviewed journal articles, and his work has been continuously funded by NIH and several other foundations for over 30 years. He graduated from Lokmanya Tilak Municipal Medical College medical school.
Our Global Presence
BioPorto provides biomarkers, research antibodies and ELISA assays to scientists and clinicians around the world.
For more information on our products and services available outside of the US,
please visit our global website.